Letrozole

Bibliography

• Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol 2009. [Epub ahead of print]
   PubMedGoogle Scholar
• Brueggemeier RW. Aromatase inhibitors: new endocrine treatment of breast cancer. Semin Reprod Med 2004;22:31-43
   PubMed Web of Science ®Google Scholar
• Santen RJ, Brodie H, Simpson ER, History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev 2009;30(4):343-75.
   PubMed Web of Science ®Google Scholar
• Jordan VC. Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer. 2008;44(1):30-8
   PubMed Web of Science ®Google Scholar
• Santen RJ, Samojlik E, Lipton A, Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. Cancer 1977;39(Suppl 6):2948-58
   PubMed Web of Science ®Google Scholar
• Santen RJ, Santner S, Davis B, Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 1978;47:1257-65
   PubMed Web of Science ®Google Scholar
• Santen RJ, Demers LM, Lynch J, Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. J Clin Endocrinol Metab 1991;73:99-106
   PubMed Web of Science ®Google Scholar
• Falkson CI, Falkson HC. A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer. Ann Oncol 1996;7:465-9
   PubMed Web of Science ®Google Scholar
• Thuerlimann B, Beretta K, Bacchi M, First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol 1996;7:471-9
   PubMed Web of Science ®Google Scholar
• Dowsett M, Coombes RC. Second generation aromatase inhibitor–4-hydroxyandrostenedione. Breast Cancer Res Treat 1994;30:81-7
   PubMed Web of Science ®Google Scholar
• Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 2004;9:126-36
   PubMed Web of Science ®Google Scholar
• Reddy P. A review of the newer aromatase inhibitors in the management of metastatic breast cancer. J Clin Pharm Ther 1998;23(2):81-90
   PubMed Web of Science ®Google Scholar
• Buzdar AU. New generation aromatase inhibitors–from the advanced to the adjuvant setting. Breast Cancer Res Treat 2002;75(Suppl 1):S13-7; discussion S33-5
   PubMed Web of Science ®Google Scholar
• Bhatnagar AS. The early days of letrozole. Breast Cancer Res Treat 2007;105:3-5
   PubMed Web of Science ®Google Scholar
• Iveson TJ, Smith IE, Ahern J, Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab 1993;77:324-31
   PubMed Web of Science ®Google Scholar
• Iveson TJ, Smith IE, Ahern J, Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 1993;53:266-70
   PubMed Web of Science ®Google Scholar
• Trunet PF, Mueller P, Bhatnagar AS, Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20267, in healthy male subjects. J Clin Endocrinol Metab 1993;77:319-23
   PubMed Web of Science ®Google Scholar
• Dombernowsky P, Smith I, Falkson G, Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-61
   PubMed Web of Science ®Google Scholar
• Buzdar A, Douma J, Davidson N, Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19:3357-66
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y, Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-606, Erratum in: J Clin Oncol 2001;19:3302
   PubMed Web of Science ®Google Scholar
• Femara package insert. East Hanover, NJ; Novartis Pharmaceuti-cals Corp., 2005
   Google Scholar
• Smith IE, Norton A. Fadrozole and letrozole in advanced breast cancer: clinical and biochemical effects. Breast Cancer Res Treat 1998;49(Suppl 1):S67-71, discussion S73-7
   PubMedGoogle Scholar
• Bhatnagar AS. The discovery and mechanism of action of letrozole. Breast Cancer Res Treat 2007;105:7-17
   PubMed Web of Science ®Google Scholar
• Bhatnagar AS, Brodie AMH, Long BJ, Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem Mol Biol 2001;76:199-202
   PubMed Web of Science ®Google Scholar
• Bhatnagar AS, Hausler A, Schieweck K, Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 1990;37:1021-7
   PubMed Web of Science ®Google Scholar
• Miller WR. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr Relat Cancer 1999;6:187-95
   PubMed Web of Science ®Google Scholar
• Geisler J, Haynes B, Anker G, Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002;20:751-7
   PubMed Web of Science ®Google Scholar
• Haynes BP, Dowsett M, Miller WR, The pharmacology of letrozole. J Steroid Biochem Mol Biol 2003;87:35-45
   PubMed Web of Science ®Google Scholar
• Lipton A, Demers LM, Harvey HA, Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 1995;75:2132-8
   PubMed Web of Science ®Google Scholar
• Bisagni G, Cocconi G, Scaglione F, Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. Ann Oncol 1996;7:99-102
   PubMed Web of Science ®Google Scholar
• Ingle JN, Johnson PA, Suman VJ, A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer 1997;80:218-24
   PubMed Web of Science ®Google Scholar
• Gershanovich M, Chaudri HA, Campos D, Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 1998;9:639-45
   PubMed Web of Science ®Google Scholar
• Rose C. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. Am J Clin Oncol 2003;26:S9-16
   PubMed Web of Science ®Google Scholar
• Mouridsen HT. Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat 2007;105:19-29
   PubMed Web of Science ®Google Scholar
• Clarke MJ. Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev 2008;4:CD000487
   PubMedGoogle Scholar
• Clarke MJ. Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2008;4:CD000486
   PubMedGoogle Scholar
• Clarke MJ. Ovarian ablation for early breast cancer. Cochrane Database Syst Rev 2008;4:CD000485
   PubMedGoogle Scholar
• Goldhirsch A, Ingle JN, Gelber RD, Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319-29
   PubMed Web of Science ®Google Scholar
• Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57
   PubMed Web of Science ®Google Scholar
• Coates AS, Keshaviah A, Thuerlimann B, Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of Study BIG 1-98. J Clin Oncol 2007;25:486-92
   PubMed Web of Science ®Google Scholar
• Mauriac L, Keshaviah A, Debled M, ; on behalf of BIG 1-98 Collaborative Group and International Breast Cancer Study Group, Berne, Switzerland. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 2007;18:859-67
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Giobbie-Hurder A, Goldhirsch A, ; BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361:766-76
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802
   PubMed Web of Science ®Google Scholar
• Goss PE, Muss HB, Ingle JN, Extended adjuvant endocrine therapy in breast cancer: current status and future directions. Clin Breast Cancer 2008;8:411-7
   PubMed Web of Science ®Google Scholar
• Eiermann W, Paepke S, Appfelstaedt J, Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527-32
   PubMed Web of Science ®Google Scholar
• Paepke S, Tulusan A, Kiesel L, A multi-center study of pre-operative treatment with letrozole for optimal duration of treatment in postmenopausal women with ER and/or PGR positive breast cancer. Proc Am Soc Clin Oncol 2003;22:321a
   Google Scholar
• Llombart-Cussac A, Galan A, Fuster C, Phase II trial with letrozole (2.8 mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PgR+ operable breast cancer. The Breast 2007;16:S49-50
   Web of Science ®Google Scholar
• Chang J, Powles TJ, Ashley SE, The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol 1996;7:671-5
   PubMed Web of Science ®Google Scholar
• Wasan KM, Goss PE, Pritchard PH, The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 2005;16:707-15
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J. A decade of letrozole: FACE. Breast Cancer Res Treat 2007;105:67-74
   PubMed Web of Science ®Google Scholar
• Ma CX, Ellis MJ. Neoadjuvant endocrine therapy for locally advanced breast cancer. Semin Oncol 2006;33:650-6
   PubMed Web of Science ®Google Scholar
• Marcom PK, Isaacs C, Harris L, The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007;102:43-9
   PubMed Web of Science ®Google Scholar
• Chu Q, Goldstein L, Murray N, A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients [abstract 3001]. J Clin Oncol 2005;23:192s
   Web of Science ®Google Scholar
• National Cancer Institute Study comparing GW572016 and letrozole versus letrozole in subjects with advanced or metastatic breast cancer. Available from: http://www.clinicaltrials.gov/show/NCT00073528. [Cited 25 Aug 2006]
   Google Scholar
• Awada A, Cardoso F, Fontaine C, A phase Ib study of the mTOR inhibitor RAD001 (everolimus) in combination with letrozole (Femara1), investigating safety and pharmacokinetics in patients with advanced breast cancer stable or slowly progressing on letrozole [abstract 6043]. Breast Cancer Res Treat 2004;88:S234
   Web of Science ®Google Scholar
• National Cancer Institute Everolimus and letrozole as preoperative therapy of primary breast cancer in post-menopausal women. Available from: http://www.clinicaltrials.gov/ct/show/NCT00107016. [Cited 25 Aug 2006]
   Google Scholar
• Baselga J, Roche H, Fumoleau P, Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3-arm, phase 2 study [abstract 1068]. Breast Cancer Res Treat 2005;94:S62
   Web of Science ®Google Scholar
• National Cancer Institute Study evaluating CCI-779 and letrozole in post-menopausal women with breast cancer. Availble from: http://www.clinicaltrials.gov/show/NCT00083993. [Cited 25 Aug 2006]
   Google Scholar
• Johnston SRD, Semiglazov V, Manikhas G, ; On behalf of the R115777 INT-22 Investigators. A randomised, blinded, phase II study of tipifarnib (Zarnestra1) combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy [abstract 5087]. Breast Cancer Res Treat 2005;94:S237
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Study of letrozole plus ZARNESTRA or placebo in the treatment of advanced breast cancer. Available from: http://www.clinicaltrials.gov/show/NCT00050141. [Cited 25 Aug 2006]
   Google Scholar
• Traina TA, Rugo H, Caravelli J, Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC) [abstract 3050]. J Clin Oncol 2006;24:133s
   Web of Science ®Google Scholar
• Aun B, Dice K, ALbarracin C, The combination of letrozole and imatinib mesylate for metastatic breast cancer [abstract 6046]. Breast Cancer Res Treat 2004;88:S235
   Web of Science ®Google Scholar